Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Seattle Genetics

Seattle Genetics

A company developing antibody-based therapies for the treatment of cancer and autoimmune diseases

Seattle Genetics, Inc. is a biotechnology company that engages in the development and commercialization of antibody-based therapies for the treatment of cancer. It has products that include Adcetris and Padcev. It is a company that is advancing a pipeline of novel therapies for solid tumors and blood-related cancers.

As Seattle Genetics expands business globally, its name has been rebranded as Seagen. The company had obtained FDA approvals for two cancer drugs and it partnered with Merck for a Phase II antibody-drug conjugate and a marketed drug.

The company was with a single product in the market, Adcetris (brentuximab vedotin), a drug that got approval in 2011 for Hodgkin’s lymphoma and approved for anaplastic large-cell lymphoma, a type of T-cell non-Hodgkin’s lymphoma. Subsequently, it won approval for its second product, Padcev (enfortumab vedotin-ejfv), for locally advanced or metastatic urothelial cancer, and it received a nod for Tukysa (tucatinib), for HER2-positive breast cancer.

Timeline

Funding Rounds

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
May 18, 2021
BioSpace
Elpis Biopharmaceuticals Strengthens Scientific Advisory Board - read this article along with other careers information, tips and advice on BioSpace
Brandon May
November 10, 2020
BioSpace
Clinical-stage gene therapy company Axovant Gene Therapies is changing its name to Sio Gene Therapies, a move that will likely further distance the company from disappointing results of its Alzheimer's candidate just three years ago.
Nick Paul
June 30, 2020
FierceBiotech
Genmab and Seattle Genetics' tisotumab vedotin has achieved a 24% response rate in cervical cancer patients, teeing the partners up to talk to the FDA about filing for accelerated approval of the antibody-drug conjugate (ADC).
May 29, 2020
BioSpace
Seattle Genetics Announces Positive Results from Exploratory Analyses of HER2CLIMB for TUKYSATM (tucatinib) in Brain Metastases Patients With HER2-Positive Breast Cancer - read this article along with other careers information, tips and advice on BioSpace
May 14, 2020
BioSpace
Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma - read this article along with other careers information, tips and advice on BioSpace
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.